THE INFLUENCE OF POINT MUTATIONS IN THE EPSTEIN-BARR VIRUS LMP1 ONCOGENE ON THE CELL CYTOSKELETON AND ACTIVATION OF INDUCIBLE FORM OF NO SYNTHASE

Cover Page


Cite item

Full Text

Abstract

One of the latent proteins encoded by the Epstein−Barr virus (EBV), the latent membrane protein 1 (LMP1), plays a key role in developing of EBV-associated human malignancies. Polymorphism of LMP1 protein is its characteristic feature. Some specific mutations in LMP1 genome have previously been detected in different geographic regions, however, the influence of these mutations on functional activity of LMP1 was not still determined. In this study we demonstrated for the first time the significance of individual point mutations among common ones observed in LMP1 and their combination on activation of the inducible form of nitric oxide synthase (iNOS). In addition, the influence of above mutations localized in the CTAR regions of the LMP1 molecule has also been investigated on structural components of the fibroblasts of the Rat1cell line.

 

About the authors

S. V. Diduk

N.N. Blokhin Russian Cancer Research Center RAMS

Author for correspondence.
Email: diduksv@rambler.ru
кандидат биологических наук, научный сотрудник лаборатории вирусного канцерогенеза НИИ канцерогенеза Российского онкологического научного центра имени Н.Н. Блохина РАМН Адрес: 115478, Москва, Каширское шоссе, д. 24 Тел.: (495) 323-57-55, факс: (495) 324-12-05 Россия

K. V. Smirnova

N.N. Blokhin Russian Cancer Research Center RAMS

Email: smirnovakv@rambler.ru
кандидат биологических наук, научный сотрудник лаборатории вирусного канцероге- неза НИИ канцерогенеза Российского онкологического научного центра имени Н.Н. Блохина РАМН Адрес: 115478, Москва, Каширское шоссе, д. 24 Россия

V. E. Gurtsevitch

N.N. Blokhin Russian Cancer Research Center RAMS

Email: gurtsevitch@yahoo.com
доктор медицинских наук, профессор, заведующий лабораторией вирусного канце- рогенеза НИИ канцерогенеза Российского онкологического научного центра имени Н.Н. Блохина РАМН Адрес: 115478, Москва, Каширское шоссе, д. 24 Тел.: (495) 324-25-64 Россия

References

  1. Young L.S., Rickinson A.B. Epstein−Barr virus: 40 years on. Nat. Rev. Cancer. 2004; 4 (10): 757−768.
  2. Young L., Alfieri C., Hennessy K. et al. Expression of Epstein−Barr virus trasformation-associated genes in tissues of patients with EBV lymphoproliferative diseases. New Engl. J. Med. 1989; 321: 1080−1085.
  3. Kaye K., Izumi K., Kieff E. Epstein−Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA. 1993; 90: 9150−9154.
  4. Moorthy R.K., Thorley-Lawson D.A. All three domains of the Epstein−Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J. Virol. 1993; 67: 1638−1646.
  5. Mosialos G., Birkenbach M., Yalamanchili R. et al. The Epstain−Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 1995; 80: 389−399.
  6. Mosialos G. Cytokine signaling and Epstein−Barr virus-mediated cell transformation. Cytokine & Growth Factor. 2001; 12: 259–270.
  7. McFarland M.D.C., Izumi K.M., Mosialos G. Epstein−Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kB. Oncogene. 1999; 18: 6959–6964.
  8. Wu L., Nakano H., Wu Z. The C-terminal activating region 2 of the Epstein−Barr virus-encoded latent membrane protein 1 activates NF-kB through TRAF6 and TAK1. J. Biol. Chem. 2006; 281 (4): 2162–2169.
  9. Eliopoulos A.G., Young L.S. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein−Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene. 1998; 16: 1731−1742.
  10. Eliopoulos, A.G., Blake, S.M., Floettmann, J.E. et al. Epstein−Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J. Virol. 1999; 73: 1023−1025.
  11. Lam N., Sugden B. CD40 and its viral mimic, LMP1: similar means to different ends. Cell. Signal. 2003; 15: 9−16.
  12. Dawson C.W., Tramountanis G., Eliopoulos A.G., Young L.S. Epstein−Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J. Biolog. Chem. 2003; 278 (6): 3694–3704.
  13. Wakisaka N., Kondo S., Yoshizaki T. et al. Epstein−Barr virus latent membrane protein 1 induces hypoxia-inducible factor 1α. Molecular and Cellular Biol. 2004; 24 (12): 5223−5234.
  14. Yu J., Tsai H., Wu C. et al. Induction of inducible nitric oxide synthase by Epstein−Barr virus B95-8-derived LMP1 in BALB/3T3 cells promotes stress-induced cell death and impaires LMP1-mediated transformation. Oncogene. 2002; 21: 8047−8061.
  15. Chew M.M., Gan S.Y., Khoo A.S., Tan E.L. Interleukins, laminin and Epstein−Barr virus latent protein 1 (EBV LMP1) promote metastatic phenotype in nasopharyngeal carcinoma. BMC Cancer. 2010; 10: 574.
  16. Smirnova K.V., Diduk S.V., Gurtsevich V.E. Functional analysis of variants of latent membrane protein 1 (LMP1) of Epstein-Barr virus in patients with lymphoproliferative diseases. Biomeditsinskaya khimiya = Biomedical chemistry. 2010; 3: 273−284.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 "Paediatrician" Publishers LLC